Table 1.
Clinical characteristics of patients.
| Characteristics | The internal set (n=125) No. of patients (%) | The external set (n=69) No. of patients (%) | P-value |
|---|---|---|---|
| Gender (female/male) | 55/70 (44.0/56.0) | 32/37(46.4/53.6) | 0.750 |
| Age (<65/≥65) | 92/33 (73.6/26.4) | 40/29 (58.0/42.0) | 0.025* |
| Mean ± SD | 58.1 ± 9.60 | 62.1 ± 8.83 | 0.005* |
| KPS (<80/≥80) | 11/114 (8.8/91.2) | 11/58 (15.9/84.1) | 0.133 |
| Smoking history | 46 (36.8) | 32 (46.4) | 0.193 |
| N stage | 0.360 | ||
| N0-1 | 39 (31.2) | 26 (37.7) | |
| N2-3 | 86 (68.8) | 43 (62.3) | |
| T stage | 0.748 | ||
| T1-2 | 86 (68.8) | 54 (78.3) | |
| T3-4 | 39 (31.2) | 15 (21.7) | |
| Number of bone metastasis | 0.543 | ||
| 1 | 49 (39.2) | 24 (34.8) | |
| 2-5 | 76 (60.8) | 45 (65.2) | |
| Gene alternation status | 0.051 | ||
| EGFR-sensitive mutations | 64 (51.2) | 25 (36.2) | |
| ALK mutation | 8 (6.4) | 1 (1.5) | |
| EGFR unsensitive mutations | 10 (8.0) | 6 (8.7) | |
| Other mutations | 7 (5.6) | 4 (5.8) | |
| No | 36 (28.8) | 33 (47.8) | |
| Antiresorptive drugs | 104 (83.2) | 48 (69.6) | 0.027* |
| ALP (U/L) | 117.5 ± 55.55 | 95.4 ± 35.81 | 0.001* |
| Albumin (g/L) | 41.9 ± 4.73 | 40.2 ± 4.72 | 0.017* |
| c-Ca | 2.3 ± 0.14 | 2.3 ± 0.10 | 0.340 |
| Leukocyte (109/L) | 7.5 ± 2.50 | 7.1 ± 2.29 | 0.294 |
| NLR | 3.5 ± 3.03 | 3.7 ± 2.39 | 0.614 |
| PLR | 185.1 ± 89.53 | 204.5 ± 129.39 | 0.271 |
| SII | 966.0 ± 714.59 | 1050.3 ± 943.18 | 0.485 |
*P < 0.05; KPS, karnofsky performance status scores; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; PLR, platelet to lymphocyte ratio; NLR, neutrophils to lymphocyte ratio; SII, systemic inflammatory index; ALP, alkaline phosphatase.